{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:44:33Z","timestamp":1791305073678,"version":"4.3.1"},"reference-count":144,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Card Fail Rev"],"abstract":"<jats:p>Acute heart failure with preserved ejection fraction (acute heart failure\u2013heart failure with preserved ejection fraction) is increasingly prevalent, resulting from the interaction between a dysfunctional ventricle, the patient\u2019s comorbidity burden and acute triggers. Patients are typically older, commonly female and have cardiometabolic, renal, arrhythmic, ischaemic and inflammatory comorbidities that produce vulnerability to decompensation. Acute episodes manifest with pulmonary and\/or systemic congestion, from abrupt rises in left-sided filling pressures due to cardiac and arterial stiffness driven by neurohormonal activation and inflammation. Congestion and elevated blood pressure are common, but clinical presentation is more heterogeneous, reflecting the haemodynamic abnormalities, severity of triggers and comorbidity load. Diagnosis relies on integrating clinical context, echocardiography, adjusted thresholds of natriuretic peptides, and invasive and\/or stress haemodynamics when diagnosis is uncertain. Management requires individualised decongestion, alongside treatment of precipitants. Early initiation of disease-modifying therapies after haemodynamic stability, including sodium\u2013glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists and glucagon-like peptide-1 receptor agonists, improves outcomes. Acute heart failure\u2013heart failure with preserved ejection fraction follows a relapsing\u2013remitting trajectory, underscoring the importance of comorbidity management, structured follow-up and preventive strategies.<\/jats:p>","DOI":"10.15420\/cfr.2025.56","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:30:38Z","timestamp":1782844238000},"source":"Crossref","is-referenced-by-count":1,"title":["Acute Heart Failure in Heart Failure with Preserved Ejection Fraction: A State-of-the-art Review from an International Expert Group"],"prefix":"10.15420","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0596-2877","authenticated-orcid":false,"given":"Razvan I","family":"Radu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2374-6449","authenticated-orcid":false,"given":"Beth","family":"Davison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5641-8332","authenticated-orcid":false,"given":"Sean P","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8715-7753","authenticated-orcid":false,"given":"Alexandre","family":"Mebazaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7732-0887","authenticated-orcid":false,"given":"Gianluigi","family":"Savarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7924-9751","authenticated-orcid":false,"given":"\u00d2scar","family":"Mir\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Morishetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4611-8413","authenticated-orcid":false,"given":"Oliviana","family":"Geavlete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2624-9213","authenticated-orcid":false,"given":"Maurizio","family":"Volterrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3855-1815","authenticated-orcid":false,"given":"Marianna","family":"Adamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1411-4482","authenticated-orcid":false,"given":"Lars H","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4023-2263","authenticated-orcid":false,"given":"Giuseppe MC","family":"Rosano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6691-8568","authenticated-orcid":false,"given":"Marco","family":"Metra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8683-7044","authenticated-orcid":false,"given":"Mandeep R","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6235-984X","authenticated-orcid":false,"given":"Alberto","family":"Palazzuoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9589-0023","authenticated-orcid":false,"given":"Marija","family":"Polovina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4563-1071","authenticated-orcid":false,"given":"Andrew P","family":"Ambrosy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6851-4417","authenticated-orcid":false,"given":"Anika S","family":"Naidu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0805-8683","authenticated-orcid":false,"given":"Stefan D","family":"Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7683-4720","authenticated-orcid":false,"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3197-3628","authenticated-orcid":false,"given":"Ovidiu","family":"Chioncel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2771-4260","authenticated-orcid":false,"given":"Andrew JS","family":"Coats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9613-3339","authenticated-orcid":false,"given":"Gad","family":"Cotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Segar MW, Patel KV, Ayers C, et al. Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis. Eur J Heart Fail 2020;22:148\u201358. https:\/\/doi.org\/10.1002\/EJHF.1621; PMID:\u00a031637815.","DOI":"10.1002\/ejhf.1621"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Shah SJ, Katz DH, Selvaraj S, et al. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation 2015;131:269\u201379. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.010637; PMID:\u00a025398313.","DOI":"10.1161\/CIRCULATIONAHA.114.010637"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Adamo M, Chioncel O, Benson L, et al. Prevalence, clinical characteristics and outcomes of heart failure patients with or without isolated or combined mitral and tricuspid regurgitation: an analysis from the ESC-HFA Heart Failure Long-Term Registry. Eur J Heart Fail 2023;25:1061\u201371. https:\/\/doi.org\/10.1002\/EJHF.2929; PMID:\u00a037365841.","DOI":"10.1002\/ejhf.2929"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Adamo M, Chioncel O, Pagnesi M, et al. Epidemiology, pathophysiology, diagnosis and management of chronic right-sided heart failure and tricuspid regurgitation. A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. In: Eur J Heart Fail 2024;26:18\u201333. https:\/\/doi.org\/10.1002\/EJHF.3106; PMID:\u00a038131233.","DOI":"10.1002\/ejhf.3106"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Paulus WJ, Tsch\u00f6pe C. A novel paradigm for heart failure with preserved ejection fraction. J Am Coll Cardiol 2013;62:263\u201371. https:\/\/doi.org\/10.1016\/j.jacc.2013.02.092; PMID:\u00a023684677.","DOI":"10.1016\/j.jacc.2013.02.092"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart failure with preserved ejection fraction: JACC scientific statement. J Am Coll Cardiol 2023;81:1810\u201334. https:\/\/doi.org\/10.1016\/j.jacc.2023.01.049; PMID:\u00a037137592.","DOI":"10.1016\/j.jacc.2023.01.049"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Cotter G, Davison B. Acute heart failure is a remitting-relapsing disorder and not a step towards advanced heart failure: implications for decongestion therapy. Eur J Heart Fail 2023;25:933\u20135. https:\/\/doi.org\/10.1002\/EJHF.2916; PMID:\u00a037212190.","DOI":"10.1002\/ejhf.2916"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Kap\u0142on-Cie\u015blicka A, Benson L, Chioncel O, et al. A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry. Eur J Heart Fail 2022;24:335\u201350. https:\/\/doi.org\/10.1002\/EJHF.2408; PMID:\u00a034962044.","DOI":"10.1002\/ejhf.2408"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Anker SD, Usman MS, Anker MS, et al. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension. Eur J Heart Fail 2023;25:936\u201355. https:\/\/doi.org\/10.1002\/EJHF.2894; PMID:\u00a037461163.","DOI":"10.1002\/ejhf.2894"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Siddiqi TJ, Khan MS, Waqas SA, et al. Effect of glucagon-like peptide-1 receptor agonists on heart failure outcomes and cardiovascular death across varying cardiovascular-kidney-metabolic comorbidity. Eur J Heart Fail 2025;27:2844\u201354. https:\/\/doi.org\/10.1002\/EJHF.70048; PMID:\u00a040977256.","DOI":"10.1002\/ejhf.70048"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Abdelhamid M, Abdrabou MM, Faris E, et al. Glucagon-like Peptide-1 receptor agonists in heart failure: mechanisms, evidence and identifying optimal candidates. Card Fail Rev 2025;11:e28. https:\/\/doi.org\/10.15420\/CFR.2025.17; PMID:\u00a041234532.","DOI":"10.15420\/cfr.2025.17"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"COTTER G, DAVISON B, BIEGUS J, et al. Increasing evidence supports the benefits of rapid uptitration of the neurohormonal blockade in HFmrEF\/HFpEF patients with AHF. J Card Fail 2025;31:721\u20134. https:\/\/doi.org\/10.1016\/j.cardfail.2024.12.015; PMID:\u00a039947427.","DOI":"10.1016\/j.cardfail.2024.12.015"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Pagnesi M, Metra M, Cohen-Solal A, et al. Uptitrating treatment after heart failure hospitalization across the spectrum of left ventricular ejection fraction. J Am Coll Cardiol 2023;81:2131\u201344. https:\/\/doi.org\/10.1016\/j.jacc.2023.03.426; PMID:\u00a037257948.","DOI":"10.1016\/j.jacc.2023.03.426"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Chioncel O, Mebazaa A, Maggioni AP, et al. Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. Eur J Heart Fail 2019;21:1338\u201352. https:\/\/doi.org\/10.1002\/EJHF.1492; PMID:\u00a031127678.","DOI":"10.1002\/ejhf.1492"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Lund LH, Crespo-Leiro MG, Laroche C, et al. Heart failure in Europe: guideline-directed medical therapy use and decision making in chronic and acute, pre-existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction \u2013 the ESC EORP Heart Failure III Registry. Eur J Heart Fail 2024;26:2487\u2013501. https:\/\/doi.org\/10.1002\/EJHF.3445; PMID:\u00a039257278.","DOI":"10.1002\/ejhf.3445"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Tromp J, Beusekamp JC, Ouwerkerk W, et al. Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the REPORT-HF registry. Eur J Heart Fail 2022;24:645\u201352. https:\/\/doi.org\/10.1002\/EJHF.2431; PMID:\u00a035064730.","DOI":"10.1002\/ejhf.2431"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Cotter G, Cotter-Davison B, Ogah OS. The burden of heart failure in Africa. Eur J Heart Fail 2013;15:829\u201331. https:\/\/doi.org\/10.1093\/EURJHF\/HFT073; PMID:\u00a023650132.","DOI":"10.1093\/eurjhf\/hft073"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Feng J, Zhang Y, Zhang J. Epidemiology and burden of heart failure in Asia. JACC Asia 2024;4:249\u201364. https:\/\/doi.org\/10.1016\/j.jacasi.2024.01.013; PMID:\u00a038660101.","DOI":"10.1016\/j.jacasi.2024.01.013"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Abdelhamid M, Al Ghalayini K, Al-Humood K, et al. Regional expert opinion: management of heart failure with preserved ejection fraction in the Middle East, North Africa and Turkey. ESC Heart Fail 2023;10:2773\u201387. https:\/\/doi.org\/10.1002\/EHF2.14456; PMID:\u00a037530028.","DOI":"10.1002\/ehf2.14456"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Chioncel O, Benson L, Crespo-Leiro MG, et al. Comprehensive characterization of non-cardiac comorbidities in acute heart failure: an analysis of ESC-HFA EURObservational Research Programme Heart Failure Long-Term Registry. Eur J Prev Cardiol 2023;30:1346\u201358. https:\/\/doi.org\/10.1093\/EURJPC\/ZWAD151; PMID:\u00a037172316.","DOI":"10.1093\/eurjpc\/zwad151"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Gomez KA, Tromp J, Figarska SM, et al. Distinct comorbidity clusters in patients with acute heart failure: data from RELAX-AHF-2. JACC Heart Fail 2024;12:1762\u201374. https:\/\/doi.org\/10.1016\/j.jchf.2024.04.028; PMID:\u00a038970586.","DOI":"10.1016\/j.jchf.2024.04.028"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Xu S, Gu Z, Zhu W, Feng S. Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction. ESC Heart Fail 2025;12:799\u2013808. https:\/\/doi.org\/10.1002\/EHF2.14958; PMID:\u00a038993173.","DOI":"10.1002\/ehf2.14958"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Morgen CS, Haase CL, Oral TK, et al. Obesity, cardiorenal comorbidities, and risk of hospitalization in patients with heart failure with preserved ejection fraction. Mayo Clin Proc 2023;98:1458\u201368. https:\/\/doi.org\/10.1016\/j.mayocp.2023.07.008; PMID:\u00a037565948.","DOI":"10.1016\/j.mayocp.2023.07.008"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Cotter G, Petrie MC, Butler J, et al. Obesity and inflammation in chronic and acute heart failure. Heart Fail Rev 2025;30:923\u201330. https:\/\/doi.org\/10.1007\/s10741-025-10518-x; PMID:\u00a040319221.","DOI":"10.1007\/s10741-025-10518-x"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Mesquita T, Lin YN, Ibrahim A. Chronic low-grade inflammation in heart failure with preserved ejection fraction. Aging Cell 2021;20:e13453. https:\/\/doi.org\/10.1111\/ACEL.13453; PMID:\u00a034382743.","DOI":"10.1111\/acel.13453"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Hassoun R, Hamdani N. Inflammation in HFpEF: crucial or ancillary? Circ Heart Failure 2023;16:e010887. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.123.010887; PMID:\u00a037497625.","DOI":"10.1161\/CIRCHEARTFAILURE.123.010887"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Carson P, Massie BM, Mckelvie R, et al. The irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) trial: rationale and design. J Card Fail 2005;11:576\u201385. https:\/\/doi.org\/10.1016\/j.cardfail.2005.06.432; PMID:\u00a016230259.","DOI":"10.1016\/j.cardfail.2005.06.432"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Redfield MM, Anstrom KJ, Levine JA, et al. Isosorbide mononitrate in heart failure with preserved ejection fraction. N Engl J Med 2015;373:2314\u201324. https:\/\/doi.org\/10.1056\/NEJMOA1510774; PMID:\u00a026549714.","DOI":"10.1056\/NEJMoa1510774"},{"key":"ref28","unstructured":"Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019;381:1609\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1908655; PMID:\u00a031475794."},{"key":"ref29","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451\u201361. https:\/\/doi.org\/10.1056\/NEJMOA2107038; PMID:\u00a034449189."},{"key":"ref30","unstructured":"Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022;387:1089\u201398. https:\/\/doi.org\/10.1056\/NEJMOA2206286; PMID:\u00a036027570."},{"key":"ref31","unstructured":"Piepoli MF, Adamo M, Barison A, et al. Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. Eur J Heart Fail 2022;24:143\u201368. https:\/\/doi.org\/10.1002\/EJHF.2351; PMID:\u00a035083829."},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Uchmanowicz I, J\u0119drzejczyk M, Lee CS, et al. Multiprofessional interventions for frailty in patients with heart failure: a comprehensive review. Curr Heart Fail Rep 2025;22:37. https:\/\/doi.org\/10.1007\/s11897-025-00727-8; PMID:\u00a041205104.","DOI":"10.1007\/s11897-025-00727-8"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Ceelen DCH, ter Maaten JM, Voordes GHD, et al. Clinical profiles and prognostic impact of residual intravascular and tissue congestion in acute heart failure. Eur J Heart Fail 2025;27:3123\u201333. https:\/\/doi.org\/10.1002\/EJHF.70091; PMID:\u00a041215726.","DOI":"10.1002\/ejhf.70091"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Pugliese NR, Pellicori P, Filidei F, et al. Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions. Cardiovasc Res 2023;118:3536\u201355. https:\/\/doi.org\/10.1093\/CVR\/CVAC133; PMID:\u00a036004819.","DOI":"10.1093\/cvr\/cvac133"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Van Aelst LNL, Arrigo M, Placido R, et al. Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion. Eur J Heart Fail 2018;20:738\u201347. https:\/\/doi.org\/10.1002\/EJHF.1050; PMID:\u00a029251818.","DOI":"10.1002\/ejhf.1050"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Loungani RS, Teerlink JR, Metra M, et al. Cause of death in patients with acute heart failure: insights from RELAX-AHF-2. JACC Heart Fail 2020;8:999\u20131008. https:\/\/doi.org\/10.1016\/j.jchf.2020.09.010; PMID:\u00a033189635.","DOI":"10.1016\/j.jchf.2020.09.010"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Shahim B, Kapelios CJ, Savarese G, Lund LH. Global public health burden of heart failure: an updated review. Card Fail Rev 2023;9:e11. https:\/\/doi.org\/10.15420\/CFR.2023.05; PMID:\u00a037547123.","DOI":"10.15420\/cfr.2023.05"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Rubio-Gracia J, Demissei BG, ter Maaten JM, et al. Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. Int J Cardiol 2018;258:185\u201391. https:\/\/doi.org\/10.1016\/j.ijcard.2018.01.067; PMID:\u00a029544928.","DOI":"10.1016\/j.ijcard.2018.01.067"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Metra M, Cotter G, Gheorghiade M, et al. The role of the kidney in heart failure. Eur Heart J 2012;33:2135\u201342. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHS205; PMID:\u00a022888113.","DOI":"10.1093\/eurheartj\/ehs205"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure. J Am Coll Cardiol 2007;50:768\u201377. https:\/\/doi.org\/10.1016\/j.jacc.2007.04.064; PMID:\u00a017707182.","DOI":"10.1016\/j.jacc.2007.04.064"},{"key":"ref41","unstructured":"Ponikowski P, Kirwan BA, Anker SD, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet 2020;396:1895\u2013904. https:\/\/doi.org\/10.1016\/S0140-6736(20)32339-4; PMID:\u00a033197395."},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Samson R, Jaiswal A, Ennezat PV, et al. Clinical phenotypes in heart failure with preserved ejection fraction. J Am Heart Assoc 2016;5:e002477. https:\/\/doi.org\/10.1161\/JAHA.115.002477; PMID:\u00a026811159.","DOI":"10.1161\/JAHA.115.002477"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Lewis GA, Schelbert EB, Williams SG, et al. Biological phenotypes of heart failure with preserved ejection fraction. J Am Coll Cardiol 2017;70:2186\u2013200. https:\/\/doi.org\/10.1016\/j.jacc.2017.09.006; PMID:\u00a029050567.","DOI":"10.1016\/j.jacc.2017.09.006"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Sanders-Van Wijk S, Tromp J, Beussink-Nelson L, et al. Proteomic evaluation of the comorbidity-inflammation paradigm in heart failure with preserved ejection fraction: results from the PROMIS-HFpEF study. Circulation 2020;142:2029\u201344. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.045810; PMID:\u00a033034202.","DOI":"10.1161\/CIRCULATIONAHA.120.045810"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Kao DP, Lewsey JD, Anand IS, et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail 2015;17:925\u201335. https:\/\/doi.org\/10.1002\/EJHF.327; PMID:\u00a026250359.","DOI":"10.1002\/ejhf.327"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Sotomi Y, Hikoso S, Komukai S, et al. Phenotyping of acute decompensated heart failure with preserved ejection fraction. Heart 2022;108:1553\u201361. https:\/\/doi.org\/10.1136\/HEARTJNL-2021-320270; PMID:\u00a034987067.","DOI":"10.1136\/heartjnl-2021-320270"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Sotomi Y, Tamaki S, Hikoso S, et al. Pathophysiological insights into machine learning-based subphenotypes of acute heart failure with preserved ejection fraction. Heart 2024;110:441\u20137. https:\/\/doi.org\/10.1136\/HEARTJNL-2023-323059; PMID:\u00a037827559.","DOI":"10.1136\/heartjnl-2023-323059"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Sotomi Y, Nagai T, Hikoso S, et al. Phenotypic characteristics of acute decompensated heart failure with preserved ejection fraction in Japanese population. JACC Asia 2024;4:566\u20138. https:\/\/doi.org\/10.1016\/j.jacasi.2024.04.011; PMID:\u00a039101112.","DOI":"10.1016\/j.jacasi.2024.04.011"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Cogliati C, Ceriani E, Gambassi G, et al. Phenotyping congestion in patients with acutely decompensated heart failure with preserved and reduced ejection fraction: the Decongestion duRing therapY for acute decOmpensated heart failure in HFpEF vs HFrEF- DRY-OFF study. Eur J Intern Med 2022;97:69\u201377. https:\/\/doi.org\/10.1016\/J.EJIM.2021.11.010; PMID:\u00a034844795.","DOI":"10.1016\/j.ejim.2021.11.010"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Verma S, Petrie MC, Borlaug BA, et al. Inflammation in obesity-related HFpEF. J Am Coll Cardiol 2024;84:1646\u201362. https:\/\/doi.org\/10.1016\/j.jacc.2024.08.028; PMID:\u00a039217564.","DOI":"10.1016\/j.jacc.2024.08.028"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Nakagawa A, Yasumura Y, Yoshida C, et al. Prognostic importance of right ventricular-vascular uncoupling in acute decompensated heart failure with preserved ejection fraction. Circ Cardiovasc Imaging 2020;13:e011430. https:\/\/doi.org\/10.1161\/CIRCIMAGING.120.011430; PMID:\u00a033198494.","DOI":"10.1161\/CIRCIMAGING.120.011430"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Li R, Liu Y, Zhao Z, et al. Machine learning-based phenotyping and assessment of treatment responses in heart failure with preserved ejection fraction. EClinicalmedicine 2025;88:103462. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103462; PMID:\u00a041181830.","DOI":"10.1016\/j.eclinm.2025.103462"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Bishu K, Redfield MM. Acute heart failure with preserved ejection fraction: unique patient characteristics and targets for therapy. Curr Heart Fail Rep 2013;10:190\u20137. https:\/\/doi.org\/10.1007\/S11897-013-0149-5; PMID:\u00a023868335.","DOI":"10.1007\/s11897-013-0149-5"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Youn JC, Ahn Y, Jung HO. Pathophysiology of heart failure with preserved ejection fraction. Heart Fail Clin 2021;17:327\u201335. https:\/\/doi.org\/10.1016\/j.hfc.2021.02.001; PMID:\u00a034051965.","DOI":"10.1016\/j.hfc.2021.02.001"},{"key":"ref55","unstructured":"Butler J, Fonarow GC, Zile MR, et al. Developing therapies for heart failure with preserved ejection fraction. Current state and future directions. JACC Heart Fail 2014;2:97\u2013112. https:\/\/doi.org\/10.1016\/j.jchf.2013.10.006; PMID:\u00a024720916."},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 2014;11:507\u201315. https:\/\/doi.org\/10.1038\/NRCARDIO.2014.83; PMID:\u00a024958077.","DOI":"10.1038\/nrcardio.2014.83"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Miranda-Silva D, Lima T, Rodrigues P, et al. Mechanisms underlying the pathophysiology of heart failure with preserved ejection fraction: the tip of the iceberg. Heart Fail Rev 2021;26:453\u201378. https:\/\/doi.org\/10.1007\/S10741-020-10042-0; PMID:\u00a033411091.","DOI":"10.1007\/s10741-020-10042-0"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Cotter G, Moshkovitz Y, Milovanov O, et al. Acute heart failure: a novel approach to its pathogenesis and treatment. Eur J Heart Fail 2002;4:227\u201334. https:\/\/doi.org\/10.1016\/S1388-9842(02)00017-X; PMID:\u00a012034145.","DOI":"10.1016\/S1388-9842(02)00017-X"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Ali D, Tran P, Weight N, et al. Heart failure with preserved ejection fraction (HFpEF) pathophysiology study (IDENTIFY-HF): rise in arterial stiffness associates with HFpEF with increase in comorbidities. Eur Heart J Suppl 2021;42(1)(Suppl 1):722. https:\/\/doi.org\/10.1093\/eurheartj\/ehab724.0722.","DOI":"10.1093\/eurheartj\/ehab724.0722"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Bezati S, Velliou M, Ventoulis I, et al. Infection as an under-recognized precipitant of acute heart failure: prognostic and therapeutic implications. Heart Fail Rev 2023;28:893\u2013904. https:\/\/doi.org\/10.1007\/s10741-023-10303-8; PMID:\u00a036897491.","DOI":"10.1007\/s10741-023-10303-8"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Palin V, Brown O, Hamilton F, et al. Infection in people with heart failure: an overlooked cause of adverse outcomes. Clin Med 2025;25:100497. https:\/\/doi.org\/10.1016\/j.clinme.2025.100497; PMID:\u00a040796058.","DOI":"10.1016\/j.clinme.2025.100497"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Naidu AS, Chioncel O, Butler J, et al. Precipitants of acute heart failure: a state-of-the-art review from an international expert group. Card Fail Rev 2026. https:\/\/doi.org\/10.15420\/cfr.2025.49. In press.","DOI":"10.15420\/cfr.2025.50"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Chen CY, Lee CH, Lin HW, et al. Impact of infection-related admission in patients with heart failure: a 10 years national cohort study. Sci Rep 2023;13:6941. https:\/\/doi.org\/10.1038\/s41598-023-34028-8; PMID:\u00a037117486.","DOI":"10.1038\/s41598-023-34028-8"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Seko Y, Kato T, Morimoto T, et al. Newly diagnosed infection after admission for acute heart failure: from the KCHF registry. J Am Heart Assoc 2021;10:e023256. https:\/\/doi.org\/10.1161\/JAHA.121.023256; PMID:\u00a034730004.","DOI":"10.1161\/JAHA.121.023256"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Geavlete O, Collins SP, Mebazaa A, et al. Hypertensive acute heart failure: a critical perspective on definition, epidemiology, pathophysiology, and prognosis-a narrative review: a joint session with the Romanian Society of Cardiology (part II). Heart Fail Rev 2025;30:1323\u201340. https:\/\/doi.org\/10.1007\/S10741-025-10551-W; PMID:\u00a040892348.","DOI":"10.1007\/s10741-025-10551-w"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J 2011;32:670\u20139. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHQ426; PMID:\u00a021138935.","DOI":"10.1093\/eurheartj\/ehq426"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Parra-Lucares A, Romero-Hern\u00e1ndez E, Villa E, et al. New opportunities in heart failure with preserved ejection fraction: from bench to bedside\u2026 and back. Biomedicines 2022;11:70. https:\/\/doi.org\/10.3390\/BIOMEDICINES11010070; PMID:\u00a036672578.","DOI":"10.3390\/biomedicines11010070"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"De Luca M, Crisci G, Armentaro G, et al. Endothelial dysfunction and heart failure with preserved ejection fraction-an updated review of the literature. Life 2023;14:30. https:\/\/doi.org\/10.3390\/LIFE14010030; PMID:\u00a038255646.","DOI":"10.3390\/life14010030"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Cornuault L, Rouault P, Dupl\u00e0a C, et al. Endothelial dysfunction in heart failure with preserved ejection fraction: what are the experimental proofs? Front Physiol 2022;13:906272. https:\/\/doi.org\/10.3389\/FPHYS.2022.906272; PMID:\u00a035874523.","DOI":"10.3389\/fphys.2022.906272"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Li B, Bai WW, Guo T, et al. Statins improve cardiac endothelial function to prevent heart failure with preserved ejection fraction through upregulating circRNA-RBCK1. Nat Commun 2024;15:2953. https:\/\/doi.org\/10.1038\/S41467-024-47327-Z; PMID:\u00a038580662.","DOI":"10.1038\/s41467-024-47327-z"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Kotecha D, Lam CSP, Van Veldhuisen DJ, et al. Heart failure with preserved ejection fraction and atrial fibrillation: vicious twins. J Am Coll Cardiol 2016;68:2217\u201328. https:\/\/doi.org\/10.1016\/j.jacc.2016.08.048; PMID:\u00a027855811.","DOI":"10.1016\/j.jacc.2016.08.048"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Reddy YNV, Obokata M, Verbrugge FH, et al. Atrial dysfunction in patients with heart failure with preserved ejection fraction and atrial fibrillation. J Am Coll Cardiol 2020;76:1051\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2020.07.009; PMID:\u00a032854840.","DOI":"10.1016\/j.jacc.2020.07.009"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Yang E, Vaishnav J, Song E, et al. Atrial fibrillation is an independent risk factor for heart failure hospitalization in heart failure with preserved ejection fraction. ESC Heart Fail 2022;9:2918\u201327. https:\/\/doi.org\/10.1002\/EHF2.13836; PMID:\u00a035712815.","DOI":"10.1002\/ehf2.13836"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"De Matteis G, Burzo ML, Serra A, et al. Clinical characteristics and prognostic impact of atrial fibrillation among older patients with heart failure with preserved ejection fraction hospitalized for acute heart failure. Intern Emerg Med 2025;20:95\u2013104. https:\/\/doi.org\/10.1007\/S11739-024-03754-W; PMID:\u00a039225848.","DOI":"10.1007\/s11739-024-03754-w"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Tzoumas A, Tapp D, Crousillat D, et al. The role of coronary microvascular dysfunction in heart failure with preserved ejection fraction. JACC Adv 2025;4:102345. https:\/\/doi.org\/10.1016\/J.JACADV.2025.102345; PMID:\u00a041265388.","DOI":"10.1016\/j.jacadv.2025.102345"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Velollari O, Rommel KP, Kresoja KP, et al. Focusing on microvascular function in heart failure with preserved ejection fraction. Heart Fail Rev 2025;30:493\u2013503. https:\/\/doi.org\/10.1007\/S10741-024-10479-7; PMID:\u00a039804445.","DOI":"10.1007\/s10741-024-10479-7"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Ostrominski JW, Claggett BL, Miao ZM, et al. Cardiovascular-kidney-metabolic overlap in heart failure with mildly reduced or preserved ejection fraction: a trial-level analysis. J Am Coll Cardiol 2024;84:223\u20138. https:\/\/doi.org\/10.1016\/j.jacc.2024.05.005; PMID:\u00a038744407.","DOI":"10.1016\/j.jacc.2024.05.005"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Kang J, Park JJ, Cho YJ, et al. Predictors and prognostic value of worsening renal function during admission in HFpEF versus HFrEF: data from the KorAHF (Korean Acute Heart Failure) registry. J Am Heart Assoc 2018;7:e007910. https:\/\/doi.org\/10.1161\/JAHA.117.007910; PMID:\u00a029535141.","DOI":"10.1161\/JAHA.117.007910"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Savarese G, Schiattarella GG, Lindberg F, et al. Heart failure and obesity: translational approaches and therapeutic perspectives. A scientific statement of the Heart Failure Association of the ESC. Eur J Heart Fail 2025;27:1273\u201393. https:\/\/doi.org\/10.1002\/EJHF.3676; PMID:\u00a040328668.","DOI":"10.1002\/ejhf.3676"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Packer M, Kitzman DW. Obesity-related heart failure with a preserved ejection fraction. JACC Heart Fail 2018;6:633\u20139. https:\/\/doi.org\/10.1016\/j.jchf.2018.01.009; PMID:\u00a029525327.","DOI":"10.1016\/j.jchf.2018.01.009"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Rodrigues MM, Falc\u00e3o LM. Pathophysiology of heart failure with preserved ejection fraction in overweight and obesity \u2013 clinical and treatment implications. Int J Cardiol 2025;430:133182. https:\/\/doi.org\/10.1016\/j.ijcard.2025.133182; PMID:\u00a040120824.","DOI":"10.1016\/j.ijcard.2025.133182"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Kim MS, Kim WJ, Khera AV, et al. Association between adiposity and cardiovascular outcomes: an umbrella review and meta-analysis of observational and Mendelian randomization studies. Eur Heart J 2021;42:3388\u2013403. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAB454; PMID:\u00a034333589.","DOI":"10.1093\/eurheartj\/ehab454"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Rayner JJ, Abdesselam I, Pan J, et al. Obesity and heart failure: exploring the cardiometabolic axis. Cardiovasc Res 2025;121:1173\u201386. https:\/\/doi.org\/10.1093\/CVR\/CVAF090; PMID:\u00a040458047.","DOI":"10.1093\/cvr\/cvaf090"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Li C, Liu X, Adhikari BK, et al. The role of epicardial adipose tissue dysfunction in cardiovascular diseases: an overview of pathophysiology, evaluation, and management. Front Endocrinol 2023;14:1167952. https:\/\/doi.org\/10.3389\/FENDO.2023.1167952; PMID:\u00a037260440.","DOI":"10.3389\/fendo.2023.1167952"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Wiszniewski K, Grudniewska A, Szab\u0142owska-Gadomska I, et al. Epicardial adipose tissue-a novel therapeutic target in obesity cardiomyopathy. Int J Mol Sci 2025;26:7963. https:\/\/doi.org\/10.3390\/IJMS26167963; PMID:\u00a040869284.","DOI":"10.3390\/ijms26167963"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Rosenkranz S, Gibbs JSR, Wachter R, et al. Left ventricular heart failure and pulmonary hypertension. Eur Heart J 2016;37:942\u201354. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHV512; PMID:\u00a026508169.","DOI":"10.1093\/eurheartj\/ehv512"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Samuel Kulifay SLK, Dominic Lattanzio DSL, Brandon Mikolich BMM, Ronald Mikolich JRM. Evidence of occult right ventricular dysfunction in morbidly obese patients. Eur Heart J 2020;41(Suppl 2):ehaa946.1024. https:\/\/doi.org\/10.1093\/EHJCI\/EHAA946.1024.","DOI":"10.1093\/ehjci\/ehaa946.1024"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Ma JI, Zern EK, Parekh JK, et al. Obesity modifies clinical outcomes of right ventricular dysfunction. Circ Heart Failure 2023;16:e010524. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.123.010524; PMID:\u00a037886836.","DOI":"10.1161\/CIRCHEARTFAILURE.123.010524"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Makino T, Ishihara Y, Harada M, et al. Phenogroups and their prognosis of acute decompensated heart failure with preserved ejection fraction. Int Heart J 2024;65:841\u20138. https:\/\/doi.org\/10.1536\/IHJ.24-080; PMID:\u00a039261030.","DOI":"10.1536\/ihj.24-080"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Hahn RT, Lindenfeld JA, B\u00f6hm M, et al. Tricuspid regurgitation in patients with heart failure and preserved ejection fraction: JACC state-of-the-art review. J Am Coll Cardiol 2024;84:195\u2013212. https:\/\/doi.org\/10.1016\/j.jacc.2024.04.047; PMID:\u00a038960514.","DOI":"10.1016\/j.jacc.2024.04.047"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Matsuoka Y, Sotomi Y, Nakatani D, et al. Phenotypic trajectories from acute to stable phase in heart failure with preserved ejection fraction: insights from the PURSUIT-HFpEF study. J Am Heart Assoc 2025;14:e037567. https:\/\/doi.org\/10.1161\/JAHA.124.037567; PMID:\u00a039895530.","DOI":"10.1161\/JAHA.124.037567"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Gheorghiade M, Abraham WT, Albert NM, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006;296:2217\u201326. https:\/\/doi.org\/10.1001\/JAMA.296.18.2217; PMID:\u00a017090768.","DOI":"10.1001\/jama.296.18.2217"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"Sakane K, Kanzaki Y, Tsuda K, et al. Disproportionately low BNP levels in patients of acute heart failure with preserved vs. reduced ejection fraction. Int J Cardiol 2021;327:105\u201310. https:\/\/doi.org\/10.1016\/j.ijcard.2020.11.066; PMID:\u00a033279592.","DOI":"10.1016\/j.ijcard.2020.11.066"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"Uriel N, Torre-Amione G, Milo O, et al. Echocardiographic ejection fraction in patients with acute heart failure: correlations with hemodynamic, clinical, and neurohormonal measures and short-term outcome. Eur J Heart Fail 2005;7:815\u20139. https:\/\/doi.org\/10.1016\/J.EJHEART.2004.10.013; PMID:\u00a016087136.","DOI":"10.1016\/j.ejheart.2004.10.013"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"Pieske B, Tsch\u00f6pe C, De Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 2019;40:3297\u2013317. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHZ641; PMID:\u00a031504452.","DOI":"10.1093\/eurheartj\/ehz641"},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"Borlaug BA, Nishimura RA, Sorajja P, et al. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Failure 2010;3:588\u201395. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.109.930701; PMID:\u00a020543134.","DOI":"10.1161\/CIRCHEARTFAILURE.109.930701"},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"Tsutsui H, Albert NM, Coats AJS, et al. Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society. Eur J Heart Fail 2023;25:616\u201331. https:\/\/doi.org\/10.1002\/EJHF.2848; PMID:\u00a037098791.","DOI":"10.1002\/ejhf.2848"},{"key":"ref98","doi-asserted-by":"crossref","unstructured":"Pan D, Pellicori P, Dobbs K, et al. Prognostic value of the chest X-ray in patients hospitalised for heart failure. Clin Res Cardiol 2021;110:1743\u201356. https:\/\/doi.org\/10.1007\/s00392-021-01836-9; PMID:\u00a033754159.","DOI":"10.1007\/s00392-021-01836-9"},{"key":"ref99","doi-asserted-by":"crossref","unstructured":"Palazzuoli A, Ruocco G, Pellicori P, et al. Multi-modality assessment of congestion in acute heart failure: associations with left ventricular ejection fraction and prognosis. Curr Probl Cardiol 2024;49:102374. https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102374; PMID:\u00a038185433.","DOI":"10.1016\/j.cpcardiol.2024.102374"},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"Reddy YNV, Carter RE, Obokata M, et al. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 2018;138:861\u201370. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034646; PMID:\u00a029792299.","DOI":"10.1161\/CIRCULATIONAHA.118.034646"},{"key":"ref101","doi-asserted-by":"crossref","unstructured":"Lee DS, Stitt A, Austin PC, et al. Prediction of heart failure mortality in emergent care: a cohort study. Ann Intern Med 2012;156:767\u201375. https:\/\/doi.org\/10.7326\/0003-4819-156-11-201206050-00003; PMID:\u00a022665814.","DOI":"10.7326\/0003-4819-156-11-201206050-00003"},{"key":"ref102","doi-asserted-by":"crossref","unstructured":"Miro \u00d2, Rossello X, Gil V, et al. Predicting 30-day mortality for patients with acute heart failure in the emergency department: a cohort study. Ann Intern Med 2017;167:698\u2013705. https:\/\/doi.org\/10.7326\/M16-2726; PMID:\u00a028973663.","DOI":"10.7326\/M16-2726"},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"Naidu AS, Ambrosy AP, Cotter G, et al. Early in-hospital treatment of acute heart failure. Part 2 of the International Expert Opinion Series on AHF Management of the international expert opinion series on AHF management. ESC Heart Fail 2025;12:3826\u201343. https:\/\/doi.org\/10.1002\/EHF2.15389; PMID:\u00a041014641.","DOI":"10.1002\/ehf2.15389"},{"key":"ref104","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599\u2013726. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAB368; PMID:\u00a034447992."},{"key":"ref105","doi-asserted-by":"crossref","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. Circulation 2022;145:e895. https:\/\/doi.org\/10.1161\/CIR.0000000000001063; PMID:\u00a035363499.","DOI":"10.1161\/CIR.0000000000001073"},{"key":"ref106","doi-asserted-by":"crossref","unstructured":"Salam AM, Sulaiman K, Alsheikh-Ali AA, et al. Precipitating factors for hospitalization with heart failure: prevalence and clinical impact observations from the gulf CARE (gulf aCute heArt failuRe rEgistry). Med Princ Pract 2019;29:270\u20138. https:\/\/doi.org\/10.1159\/000503334; PMID:\u00a031522185.","DOI":"10.1159\/000503334"},{"key":"ref107","doi-asserted-by":"crossref","unstructured":"Komajda M, Isnard R, Cohen-Solal A, et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. Eur J Heart Fail 2017;19:1495\u2013503. https:\/\/doi.org\/10.1002\/EJHF.876; PMID:\u00a028462519.","DOI":"10.1002\/ejhf.876"},{"key":"ref108","doi-asserted-by":"crossref","unstructured":"\u010celutkien\u0117 J, Mebazaa A, Biegus J, et al. Counteracting the mechanisms of heart failure is the most effective way to decongest patients while improving outcomes. Card Fail Rev 2025;11:e02. https:\/\/doi.org\/10.15420\/CFR.2024.19; PMID:\u00a040018521.","DOI":"10.15420\/cfr.2024.19"},{"key":"ref109","doi-asserted-by":"crossref","unstructured":"Chioncel O, Mebazaa A, Farmakis D, et al. Pathophysiology and clinical use of agents with vasodilator properties in acute heart failure. A scientific statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail 2025;27:1067\u201388. https:\/\/doi.org\/10.1002\/EJHF.3673; PMID:\u00a040320261.","DOI":"10.1002\/ejhf.3673"},{"key":"ref110","doi-asserted-by":"crossref","unstructured":"Mullens W, Dauw J, Martens P, et al. Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med 2022;387:1185\u201395. https:\/\/doi.org\/10.1056\/NEJMOA2203094; PMID:\u00a036027559.","DOI":"10.1056\/NEJMoa2203094"},{"key":"ref111","unstructured":"Trull\u00e0s JC, Morales-Rull JL, Casado J, et al. Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. Eur Heart J 2023;44:411\u201321. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAC689; PMID:\u00a036423214."},{"key":"ref112","doi-asserted-by":"crossref","unstructured":"Schwartzenberg S, Redfield MM, From AM, et al. Effects of vasodilation in heart failure with preserved or reduced ejection fraction. J Am Coll Cardiol 2012;59:442\u201351. https:\/\/doi.org\/10.1016\/j.jacc.2011.09.062; PMID:\u00a022281246.","DOI":"10.1016\/j.jacc.2011.09.062"},{"key":"ref113","doi-asserted-by":"crossref","unstructured":"Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 1998;351:389\u201393. https:\/\/doi.org\/10.1016\/S0140-6736(97)08417-1; PMID:\u00a09482291.","DOI":"10.1016\/S0140-6736(97)08417-1"},{"key":"ref114","unstructured":"Metra M, Teerlink JR, Cotter G, et al. Effects of serelaxin in patients with acute heart failure. N Engl J Med 2019;381:716\u201326. https:\/\/doi.org\/10.1056\/NEJMOA1801291; PMID:\u00a031433919."},{"key":"ref115","doi-asserted-by":"crossref","unstructured":"Packer M, O\u2019Connor C, McMurray JJV, et al. Effect of ularitide on cardiovascular mortality in acute heart failure. N Engl J Med 2017;376:1956\u201364. https:\/\/doi.org\/10.1056\/NEJMOA1601895; PMID:\u00a028402745.","DOI":"10.1056\/NEJMoa1601895"},{"key":"ref116","doi-asserted-by":"crossref","unstructured":"Riccardi M, Pagnesi M, Chioncel O, et al. Medical therapy of cardiogenic shock: contemporary use of inotropes and vasopressors. Eur J Heart Fail 2024;26:411\u201331. https:\/\/doi.org\/10.1002\/EJHF.3162; PMID:\u00a038391010.","DOI":"10.1002\/ejhf.3162"},{"key":"ref117","doi-asserted-by":"crossref","unstructured":"Metra M, Chioncel O, Cotter G, et al. Safety and efficacy of istaroxime in patients with acute heart failure-related pre-cardiogenic shock \u2013 a multicentre, randomized, double-blind, placebo-controlled, parallel group study (SEISMiC). Eur J Heart Fail 2022;24:1967\u201377. https:\/\/doi.org\/10.1002\/EJHF.2629; PMID:\u00a035867804.","DOI":"10.1002\/ejhf.2629"},{"key":"ref118","doi-asserted-by":"crossref","unstructured":"Biegus J, Mebazaa A, Metra M, et al. Safety and efficacy of up to 60 h of iv istaroxime in pre-cardiogenic shock patients: design of the SEISMiC trial. ESC Heart Fail 2025;12:189\u201398. https:\/\/doi.org\/10.1002\/EHF2.15102; PMID:\u00a039375885.","DOI":"10.1002\/ehf2.15102"},{"key":"ref119","unstructured":"Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med 2022;28:568\u201374. https:\/\/doi.org\/10.1038\/S41591-021-01659-1; PMID:\u00a035228754."},{"key":"ref120","doi-asserted-by":"crossref","unstructured":"Damman K, Beusekamp JC, Boorsma EM, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail 2020;22:713\u201322. https:\/\/doi.org\/10.1002\/EJHF.1713; PMID:\u00a031912605.","DOI":"10.1002\/ejhf.1713"},{"key":"ref121","doi-asserted-by":"crossref","unstructured":"Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 2021;384:117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa2030183; PMID:\u00a033200892.","DOI":"10.1056\/NEJMoa2030183"},{"key":"ref122","unstructured":"Berg DD, Patel SM, Haller PM, et al. Dapagliflozin in patients hospitalized for heart failure: primary results of the DAPA ACT HF-TIMI 68 randomized clinical trial and meta-analysis of sodium-glucose Cotransporter-2 inhibitors in patients hospitalized for heart failure. Circulation 2025;152:1411\u201322. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.125.076575; PMID:\u00a040884036."},{"key":"ref123","doi-asserted-by":"crossref","unstructured":"Cox ZL, Collins SP, Hernandez GA, et al. Efficacy and safety of dapagliflozin in patients with acute heart failure. J Am Coll Cardiol 2024;83:1295\u2013306. https:\/\/doi.org\/10.1016\/j.jacc.2024.02.009; PMID:\u00a038569758.","DOI":"10.1016\/j.jacc.2024.02.009"},{"key":"ref124","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023;44:3627\u201339. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAD195; PMID:\u00a037622666."},{"key":"ref125","doi-asserted-by":"crossref","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2024;391:1475\u201385. https:\/\/doi.org\/10.1056\/NEJMOA2407107; PMID:\u00a039225278.","DOI":"10.1056\/NEJMe2410904"},{"key":"ref126","doi-asserted-by":"crossref","unstructured":"Vaduganathan M, Mentz RJ, Claggett BL, et al. Sacubitril\/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and Paragon-HF. Eur Heart J 2023;44:2982\u201393. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAD344; PMID:\u00a037210743.","DOI":"10.1093\/eurheartj\/ehad344"},{"key":"ref127","doi-asserted-by":"crossref","unstructured":"Vaduganathan M, Claggett BL, Chatur S, et al. Lifetime benefits of comprehensive medical therapy in heart failure with mildly reduced or preserved ejection fraction. Nat Med 2025;32:325\u201331. https:\/\/doi.org\/10.1038\/s41591-025-04037-3; PMID:\u00a041052644.","DOI":"10.1038\/s41591-025-04037-3"},{"key":"ref128","doi-asserted-by":"crossref","unstructured":"Cotter G, Deniau B, Davison B, et al. Optimization of evidence-based heart failure medications after an acute heart failure admission: a secondary analysis of the STRONG-HF randomized clinical trial. JAMA Cardiol 2024;9:114\u201324. https:\/\/doi.org\/10.1001\/JAMACARDIO.2023.4553; PMID:\u00a038150260.","DOI":"10.1001\/jamacardio.2023.4553"},{"key":"ref129","doi-asserted-by":"crossref","unstructured":"Chioncel O, Mebazaa A, Collins SP, et al. Contemporary perspective on acute heart failure classification: a state-of-the-art review from an international experts\u2019 group. Card Fail Rev 2026;12:e11. https:\/\/doi.org\/10.15420\/cfr.2025.50; PMID: 42339000.","DOI":"10.15420\/cfr.2025.50"},{"key":"ref130","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023;389:1069\u201384. https:\/\/doi.org\/10.1056\/NEJMOA2306963; PMID:\u00a037622681."},{"key":"ref131","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med 2024;390:1394\u2013407. https:\/\/doi.org\/10.1056\/NEJMOA2313917; PMID:\u00a038587233."},{"key":"ref132","doi-asserted-by":"crossref","unstructured":"Monzo L, Savarese G, Mullens W, et al. Pharmacological treatment for patients with obesity and heart failure: focus on glucagon-like peptide-1 receptor agonists. European Journal of Heart Failure expert consensus document. Eur J Heart Fail 2025;27:2465\u201379. https:\/\/doi.org\/10.1002\/EJHF.70082; PMID:\u00a041309245.","DOI":"10.1002\/ejhf.70082"},{"key":"ref133","doi-asserted-by":"crossref","unstructured":"Edelmann F, Gelbrich G, Dngen HD, et al. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction. J Am Coll Cardiol 2011;58:1780\u201391. https:\/\/doi.org\/10.1016\/j.jacc.2011.06.054; PMID:\u00a021996391.","DOI":"10.1016\/j.jacc.2011.06.054"},{"key":"ref134","doi-asserted-by":"crossref","unstructured":"Aminian A, Zajichek A, Arterburn DE, et al. Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity. JAMA 2019;322:1271\u201382. https:\/\/doi.org\/10.1001\/JAMA.2019.14231; PMID:\u00a031475297.","DOI":"10.1001\/jama.2019.14231"},{"key":"ref135","doi-asserted-by":"crossref","unstructured":"Garofalo M, Corso R, Tomasoni D, et al. Inflammation in acute heart failure. Front Cardiovasc Med 2023;10:1235178. https:\/\/doi.org\/10.3389\/FCVM.2023.1235178; PMID:\u00a038045909.","DOI":"10.3389\/fcvm.2023.1235178"},{"key":"ref136","unstructured":"Davison BA, Abbate A, Cotter G, et al. Effects of anti-inflammatory therapy in acute heart failure: a systematic review and meta-analysis. Heart Fail Rev 2025;30:575\u201387. https:\/\/doi.org\/10.1007\/S10741-025-10491-5; PMID:\u00a039939545."},{"key":"ref137","doi-asserted-by":"crossref","unstructured":"Krishnan S, Gogoi M, Tarrant C, et al. Healthcare needs and priorities of older people living with heart failure and frailty: a multi-perspective study of patients, carers and clinicians. BMC Geriatr 2026;26:163. https:\/\/doi.org\/10.1186\/s12877-025-06926-1; PMID:\u00a041495683.","DOI":"10.1186\/s12877-025-06926-1"},{"key":"ref138","doi-asserted-by":"crossref","unstructured":"Rubio R, Palacios B, Varela L, et al. Quality of life and experience of patients with heart failure with preserved ejection fraction and their caregivers. J Clin Med 2025;14:4715. https:\/\/doi.org\/10.3390\/JCM14134715; PMID:\u00a040649089.","DOI":"10.3390\/jcm14134715"},{"key":"ref139","doi-asserted-by":"crossref","unstructured":"Shchendrygina A, Rachina S, Cherkasova N, et al. Colchicine in patients with heart failure and preserved left ventricular ejection fraction: rationale and design of a prospective, randomised, open-label, crossover clinical trial. Open Heart 2023;10:e002360. https:\/\/doi.org\/10.1136\/OPENHRT-2023-002360; PMID:\u00a037586845.","DOI":"10.1136\/openhrt-2023-002360"},{"key":"ref140","doi-asserted-by":"crossref","unstructured":"Cotter G, Davison BA, Freund Y, et al. Burst steroid therapy for acute heart failure: the CORTAHF randomized, open-label, pilot trial. Eur J Heart Fail 2024;26:2282\u201392. https:\/\/doi.org\/10.1002\/EJHF.3452; PMID:\u00a039211989.","DOI":"10.1002\/ejhf.3452"},{"key":"ref141","doi-asserted-by":"crossref","unstructured":"Metra M, Tomasoni D, Adamo M, et al. Evidence generation and implementation of transcatheter interventions for atrioventricular valvular heart disease in heart failure: current status and future directions. Circulation 2025;151:1342\u201363. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.070411; PMID:\u00a040324027.","DOI":"10.1161\/CIRCULATIONAHA.124.070411"},{"key":"ref142","doi-asserted-by":"crossref","unstructured":"Stevenson LW, Ross HJ, Rathman LD, Boehmer JP. Remote monitoring for heart failure management at home. J Am Coll Cardiol 2023;81:2272\u201391. https:\/\/doi.org\/10.1016\/j.jacc.2023.04.010; PMID:\u00a037286258.","DOI":"10.1016\/j.jacc.2023.04.010"},{"key":"ref143","doi-asserted-by":"crossref","unstructured":"Murray EM, Greene SJ, Rao VN, et al. Machine learning to define phenotypes and outcomes of patients hospitalized for heart failure with preserved ejection fraction: findings from ASCEND-HF. Am Heart J 2022;254:112\u201321. https:\/\/doi.org\/10.1016\/J.AHJ.2022.08.009; PMID:\u00a036007566.","DOI":"10.1016\/j.ahj.2022.08.009"}],"container-title":["Cardiac Failure Review"],"original-title":[],"link":[{"URL":"https:\/\/www.cfrjournal.com\/articleindex\/cfr.2025.56","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:38:46Z","timestamp":1782844726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cfrjournal.com\/articleindex\/cfr.2025.56"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":144,"URL":"https:\/\/doi.org\/10.15420\/cfr.2025.56","relation":{},"ISSN":["2057-7540","2057-7559"],"issn-type":[{"value":"2057-7540","type":"print"},{"value":"2057-7559","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"e16"}}